24 completed, 15 recruiting, 10 active not recruiting, 8 terminated. 70 Phase 2, 14 Phase 1, 4 Phase 3.
Follow abiraterone: new trials by email Literature Review of abiraterone trials Research Report on abiraterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer. ADT plus abiraterone or other ARPIs(apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Anhui Medical University | 40 | 2026-10-01 | 2026-08-31 |
| Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone - Prostate Cancer | Phase 2 | Recruiting | University of Nebraska | 140 | 2026-09-01 | 2026-10-19 |
| A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 180 | 2026-09-01 | 2026-07-23 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer Inavolisib, Enzalutamide, Abiraterone - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Hoffmann-La Roche | 100 | 2026-03-11 | 2026-11-06 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 181 | 2026-01-13 | 2026-11-13 |
| A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer HS-20093 for Injection, SHR3680 Tablet, Abiraterone Tablet - Prostate Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 218 | 2025-12-08 | 2026-03-03 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC AMO959, AAA617, Enzalutamide - PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 123 | 2025-12-05 | 2026-10-15 |
| Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) Abiraterone 250 mg with food + prednisone - Prostate Cancer (Diagnosis) | Phase 2 | Recruiting | SMED Clinical Research | 60 | 2025-12-01 | 2025-12-23 |
| Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer Abivertinib, Abiraterone - Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Suspended | Sorrento Therapeutics, Inc. | 100 | 2025-09-01 | 2024-03-18 |
| Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients Local treatment, Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide). - Prostate Cancer Metastatic Disease | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 192 | 2025-08-01 | 2026-03-25 |
| Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer:a Phase II Study Disitamab Vedotin (RC48), Abiraterone + prednisone - mCRPC | Phase 2 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 20 | 2025-07-20 | 2025-07-30 |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) JSB462, Abiraterone, Enzalutamide - Metastatic Hormone-sensitive Prostate Cancer | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 168 | 2025-07-07 | 2026-11-13 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C) - High Risk Prostate Carcinoma, Prostate Cancer | Phase 2 | Active not recruiting | Ivan de Kouchkovsky, MD | 32 | 2024-12-09 | 2026-09-04 |
| A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer RS-113, 160 mg, RS-113, 240 mg, RS-113, 320 mg - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Active not recruiting | R-Pharm International, LLC | 120 | 2024-10-24 | 2026-04-28 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment - Metastatic Hormone-Sensitive Prostate Cancer | Phase 2 | Unknown | Jianbin Bi | 160 | 2023-11-15 | 2023-11-18 |
| Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer Abiraterone, Biospecimen Collection, Darolutamide - Advanced Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of California, Davis | 75 | 2023-11-09 | 2026-03-13 |
| Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone Docetaxel, ADT, Abiraterone - Prostate Cancer | Phase 2 | Withdrawn | Northwestern University | 2023-10-19 | 2025-10-22 |
Showing 20 of 70. Sign in to see all of them.
Prostatic Neoplasms (44) · Prostatic Neoplasms, Castration-Resistant (4) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasm Metastasis (3) · Genital Neoplasms, Male (2) · Melanoma (2) · Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Urogenital Neoplasms (2) · Anus Neoplasms (1) · Bites and Stings (1) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Hepatocellular (1)
Novartis Pharmaceuticals (4) · Janssen Research & Development, LLC (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Masonic Cancer Center, University of Minnesota (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · University Health Network, Toronto (2) · University of Michigan Rogel Cancer Center (2) · VA Office of Research and Development (2) · Amgen (1) · Anhui Medical University (1) · Arno Therapeutics (1) · AstraZeneca (1) · British Columbia Cancer Agency (1) · Cardiff Oncology (1)
United States (42) · Spain (12) · China (11) · France (10) · Australia (9) · Canada (9) · United Kingdom (9) · Italy (8) · Brazil (6) · Germany (5) · Netherlands (5) · South Korea (5) · Belgium (4) · Poland (4) · Czechia (3)
Jingsong Zhang, MD, PhD (2) · Zachery Reichert, MD, PhD (2) · Abhishek Solanki, MD MS (1) · Albert Font, MD (1) · Anthony Joshua, MD,MBBS,PhD,FRACP (1) · Carmen Santander, MD (1) · Charles Ryan, MD (1) · Dana Rathkopf, MD (1)
PMID 18990168, PMID 22452894, PMID 22747660, PMID 25320340, PMID 25425730, PMID 26718929, PMID 26719232, PMID 27068431, PMID 28178640, PMID 28300506, PMID 28578639, PMID 29384722, PMID 29529169, PMID 29723398, PMID 29740894, PMID 30355464, PMID 30686756, PMID 30935383, PMID 31122212, PMID 31527168, PMID 31560068, PMID 32994091, PMID 33270906, PMID 33599706, PMID 33836265, PMID 34646387, PMID 34655838, PMID 34757812, PMID 34953525, PMID 35671327, PMID 36055231, PMID 36059000, PMID 36063830, PMID 36099670, PMID 36210487, PMID 37142371, PMID 37973477, PMID 38824003, PMID 39036382, PMID 39293393, PMID 39643549, PMID 39804646, PMID 39857987, PMID 40177596, PMID 40387589, PMID 40467357, PMID 40539499, PMID 40639383, PMID 40677104, PMID 40693904
2025 (3), 2017 (2), 2004 (1), 2019 (1), I01CX002277 (1), P01CA203628 (1), P30CA060553 (1), P30CA072720 (1), P30CA093373 (1), R01CA286127 (1), R01CA300454 (1)